News

Filter

Current filters:

VertexNorth America

1 to 9 of 20 results

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco

30-07-2013

US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Vertex receives first two Breakthrough Therapy Designations from US FDA

10-01-2013

During its presentation at the JP Morgan annual health care conference, US drugmaker Vertex Pharmaceuticals…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertexVX-809

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco

20-12-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

FDA warns on possible cataract risk with Vertex' Kalydeco

31-08-2012

The US Food and Drug Administration this week notified health care professionals, parents/caregivers…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Incivek and Victrelis important advances in HCV, but still unmet needs

20-06-2012

Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

1 to 9 of 20 results

Back to top